Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.
2.

[Significance of synaptic connectivity reduction for pathogenesis, clinical picture and course of schizophrenia].

Rabe-Jabłońska J.

Psychiatr Pol. 2003 Nov-Dec;37(6):951-64. Review. Polish.

PMID:
14727368
3.

White matter changes in schizophrenia: evidence for myelin-related dysfunction.

Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V.

Arch Gen Psychiatry. 2003 May;60(5):443-56. Review.

PMID:
12742865
4.

Genetic risk for white matter abnormalities in bipolar disorder.

McIntosh AM, Hall J, Lymer GK, Sussmann JE, Lawrie SM.

Int Rev Psychiatry. 2009;21(4):387-93. doi: 10.1080/09540260902962180. Review.

PMID:
20374152
5.

A review of diffusion tensor imaging studies in schizophrenia.

Kubicki M, McCarley R, Westin CF, Park HJ, Maier S, Kikinis R, Jolesz FA, Shenton ME.

J Psychiatr Res. 2007 Jan-Feb;41(1-2):15-30. Review.

6.

Oligodendrocyte pathophysiology: a new view of schizophrenia.

Segal D, Koschnick JR, Slegers LH, Hof PR.

Int J Neuropsychopharmacol. 2007 Aug;10(4):503-11. Review.

PMID:
17291369
7.

White matter abnormalities in major depression: evidence from post-mortem, neuroimaging and genetic studies.

Tham MW, Woon PS, Sum MY, Lee TS, Sim K.

J Affect Disord. 2011 Jul;132(1-2):26-36. doi: 10.1016/j.jad.2010.09.013. Review.

PMID:
20889213
8.

Possible contributions of myelin and oligodendrocyte dysfunction to schizophrenia.

Stewart DG, Davis KL.

Int Rev Neurobiol. 2004;59:381-424. Review. No abstract available.

PMID:
15006496
9.

Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia.

Takahashi N, Sakurai T, Davis KL, Buxbaum JD.

Prog Neurobiol. 2011 Jan;93(1):13-24. doi: 10.1016/j.pneurobio.2010.09.004. Review.

10.

Mechanisms of neuregulin action.

Talmage DA.

Novartis Found Symp. 2008;289:74-84; discussion 84-93. Review.

11.

Myelin, myelin-related disorders, and psychosis.

Mighdoll MI, Tao R, Kleinman JE, Hyde TM.

Schizophr Res. 2015 Jan;161(1):85-93. doi: 10.1016/j.schres.2014.09.040. Review.

PMID:
25449713
12.

[Advances in neurobiological understanding of schizophrenia. Perspectives for new therapeutic concepts].

Falkai P, Maier W.

Nervenarzt. 2006 Nov;77 Suppl 2:S65-74; quiz S75-6. Review. German.

PMID:
17072567
13.

Recent diffusion tensor imaging findings in early stages of schizophrenia.

Kyriakopoulos M, Frangou S.

Curr Opin Psychiatry. 2009 Mar;22(2):168-76. doi: 10.1097/YCO.0b013e328325aa23. Review.

PMID:
19553871
14.

Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies.

Schmitt A, Parlapani E, Gruber O, Wobrock T, Falkai P.

Eur Arch Psychiatry Clin Neurosci. 2008 Nov;258 Suppl 5:35-9. doi: 10.1007/s00406-008-5019-x. Review.

PMID:
18985292
15.

The myelin-pathogenesis puzzle in schizophrenia: a literature review.

Karoutzou G, Emrich HM, Dietrich DE.

Mol Psychiatry. 2008 Mar;13(3):245-60. Review.

PMID:
17925796
16.
17.

Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia.

Corfas G, Roy K, Buxbaum JD.

Nat Neurosci. 2004 Jun;7(6):575-80. Review.

PMID:
15162166
18.

Developmental disruptions in neural connectivity in the pathophysiology of schizophrenia.

Karlsgodt KH, Sun D, Jimenez AM, Lutkenhoff ES, Willhite R, van Erp TG, Cannon TD.

Dev Psychopathol. 2008 Fall;20(4):1297-327. doi: 10.1017/S095457940800062X. Review.

PMID:
18838043
19.

Understanding aberrant white matter development in schizophrenia: an avenue for therapy?

Walterfang M, Velakoulis D, Whitford TJ, Pantelis C.

Expert Rev Neurother. 2011 Jul;11(7):971-87. doi: 10.1586/ern.11.76. Review.

PMID:
21721915
20.

Schizophrenia, neuroimaging and connectomics.

Fornito A, Zalesky A, Pantelis C, Bullmore ET.

Neuroimage. 2012 Oct 1;62(4):2296-314. doi: 10.1016/j.neuroimage.2011.12.090. Review.

PMID:
22387165
Items per page

Supplemental Content

Support Center